麻豆传媒

At highest dose, thyroid hormone receptor-beta agonist decreased liver fat content by 45%

1-year survival reached 78% for patients who received an emergency transplant

In randomized trial, oral elafibranor induced biochemical response at 1 year in 51% of patients

Results highlight the importance of prompt recognition and treatment of acute kidney injury

AASLD president: "No way we are going to be able to transplant our way out of this"

Latest REGENERATE analysis comes on heels of REVERSE flop

Plus: Normothermic machine perfusion for liver transplants and Noom Weight for NASH

With 10% efficacy at 6 months post-treatment, a finite HBV treatment may be on the horizon

Both 50- and 28-mg doses improved fibrosis vs placebo, without worsening of NASH

Ileal bile acid transporter inhibitor could become second drug for PFIC

Significant improvements in itching, bile acid levels for rare, life-threatening liver disorder

Phase II data suggest drug is well-tolerated and can reduce cravings in this group of patients

100% success rate even without the use of hepatitis B immunoglobulin

Patients who kept their blood pressure under 140/90 mm Hg had better kidney function at 1 year